Candidemia in Cancer Patients: A Prospective, Multicenter Surveillance Study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

Citations Over TimeTop 1% of 1999 papers

Abstract

In a surveillance study of candidemia in cancer patients that was conducted by the European Organization for Research and Treatment of Cancer, 249 episodes were noted; Candida albicans was isolated in 70% (63) of the 90 cases involving patients with solid tumors (tumor patients) and in 36% (58) of the 159 involving those with hematologic disease (hematology patients). Neutropenia in tumor patients and acute leukemia and antifungal prophylaxis in hematology patients were significantly associated with non-albicans candidemia in a multivariate analysis. Overall 30-day mortality was 39% (97 of 249). In a univariate analysis, Candida glabrata was associated with the highest mortality rate (odds ratio, 2.66). Two multivariate analyses showed that mortality was associated with older age and severity of the underlying disease. Among hematology patients, additional factors associated with mortality were allogeneic bone marrow transplantation, septic shock, and lack of antifungal prophylaxis.

Related Papers

• → Variation in Susceptibility of Bloodstream Isolates ofCandida glabratato Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007(2009)129 cited
• → Risk Factors for Fluconazole-Resistant Candida glabrata Bloodstream Infections(2009)82 cited
• → Risk factors for fluconazole resistance in patients with Candida glabrata bloodstream infection: Potential impact of control group selection on characterizing the association between previous fluconazole use and fluconazole resistance(2010)20 cited
• → Selection ofCandida Glabratain Pediatric Bone Marrow Transplant Recipients Receiving Fluconazole(1994)22 cited
• → Fluconazole-Resistant Candida glabrata Pumps the Drug Out(2004)